Life Sciences

  • January 28, 2026

    New Squires Order Allows 4 Patent Reviews, Denies 25 Others

    U.S. Patent and Trademark Office Director John Squires instituted four America Invents Act patent challenges while denying 25 others in his most recent summary decision.

  • January 28, 2026

    Attys Get $2.5M In $7.5M Preterm-Birth Drug Settlement

    A New Jersey federal judge has given final approval to a $7.5 million settlement to end claims that AMAG Pharmaceuticals Inc. knew its preterm-birth prevention drug Makena was ineffective when it first marketed it, along with $2.5 million to class counsel in attorney fees.

  • January 28, 2026

    BlackRock, Eclipse Lead Cellares' $257M Funding Round

    Integrated development and manufacturing organization company Cellares, which focuses on the large-scale manufacturing of cell therapies, on Wednesday announced that it closed a $257 million funding round, bringing the South San Francisco, California-based company's total capital raised to $612 million.

  • January 28, 2026

    Crowell & Moring Adds Tech Firm IP Atty In Southern Calif.

    Crowell & Moring LLP is expanding its California team, bringing in an intellectual property attorney most recently with biotechnology firm Grail as a partner in its Orange County office in Irvine.

  • January 28, 2026

    ArentFox Schiff Launches Longevity Industry Group

    ArentFox Schiff LLP on Wednesday announced the launch of a group geared toward advising companies focused on advancing wellness, preventive health care and the longevity of life.

  • January 28, 2026

    LegitScript's Counterclaims Against PharmacyChecker Tossed

    An Oregon federal court dismissed LegitScript's counterclaims accusing PharmacyChecker.com of making false statements about the legality of importing prescription drugs, in a suit accusing the pharmacy accreditation provider of blacklisting the price-checking website.

  • January 28, 2026

    Robins Kaplan Takes Aim At Benicar MDL Fees Suit In NJ

    Robins Kaplan LLP told a New Jersey federal court Wednesday that a suit over fees the firm collected in multidistrict litigation over blood pressure medication should be thrown out, saying it "parrot[s]" claims from earlier suits that were already dismissed.

  • January 28, 2026

    Generics Makers Want Hospital Drug Data In Price-Fixing MDL

    A group of 150 hospitals suing generic-drug makers for alleged price fixing in multidistrict litigation should hand over data on their drug purchases, the drugmakers have told a Pennsylvania federal court, arguing they don't sell directly to the hospitals and therefore have no records themselves. 

  • January 28, 2026

    3rd Circ. Appears Skeptical Of Quest's Early Win In 401(k) Suit

    The Third Circuit on Wednesday pressed attorneys defending Quest Diagnostics Inc.'s pretrial defeat of a proposed class action from workers who alleged that their 401(k) savings were drained by underperforming investment funds, spotlighting the parties' disagreement over whether the lab company followed its own investment policy statement.

  • January 27, 2026

    Ohio PBM Suit Belongs In Federal Court, 6th Circ. Rules

    The Sixth Circuit on Tuesday ruled that Ohio's lawsuit accusing pharmacy benefit managers of driving up prescription prices through rebate schemes belongs in federal court, saying in an opinion recommended for publication that the suit imposes liability on conduct undertaken at the direction of a federal officer.

  • January 27, 2026

    Lasik Provider Can't Shake Wiretap Claims In Tracking Row

    The operator of a laser eye surgery website must face a proposed class action alleging it illegally shared patients' confidential medical information with Meta, a California federal judge ruled, finding that the plaintiff could continue to press allegations under state and federal wiretap law.

  • January 27, 2026

    BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial

    Artificial intelligence-driven drugmaker BioXcel Therapeutics Inc. claimed a doctor in charge of a clinical trial site in Florida tried to cover up a failure to report an adverse event by submitting a fraudulent email to a federal inspector, according to a suit filed in Florida state court.

  • January 27, 2026

    Kelley Drye Adds Ex-23andMe, Facebook Privacy Pros

    Kelley Drye & Warren LLP said Monday it is boosting its privacy and information security practice with the addition of a former 23andMe attorney in California and a former Facebook attorney in Texas.

  • January 27, 2026

    Medtronic Rival's VP Says Docs Praised Device But Didn't Buy

    A vice president in charge of sales at Applied Medical testified Tuesday in a California federal trial over his company's antitrust claims against Medtronic, and said the overwhelmingly positive feedback Applied received from surgeons who used its advanced bipolar devices often didn't result in sales. 

  • February 12, 2026

    Law360 Seeks Members For Its 2026 Editorial Boards

    Law360 is looking for avid readers of our publications to serve as members of our 2026 editorial advisory boards.

  • January 27, 2026

    Biotech Fundraising A Good Sign For Public Markets

    At the start of what many healthcare attorneys hope will be a busy year, public biotechs are raising cash, signaling a thawing public market and potentially fertile ground for IPOs.

  • January 27, 2026

    CBP's Medical Care Oversight Needs Improvement, GAO Says

    A report issued by the U.S. Government Accountability Office found that U.S. Customs and Border Protection sometimes failed to provide proper medical oversight for certain people in its custody, violating its own policies and guidance for medical care.

  • January 27, 2026

    White House Pushed To Back PTAB Rule Change Proposal

    Two groups representing inventors and startups have thrown their support behind the U.S. Patent and Trademark Office's proposal to limit America Invents Act patent reviews, saying it will give patent owners certainty and also protect against foreign challenges to domestic patents.

  • January 27, 2026

    Investors Say Teva Can't Get Early Win In Price-Fixing Suit

    Investors guided by Highfields Capital told a Connecticut federal court that Teva Pharmaceuticals can't escape their claims that its alleged collusion with other drugmakers to artificially inflate the price of generic drugs also inflated stock prices, reasoning that Teva executives falsely attributed the company's performance to factors other than the alleged price-fixing.

  • January 27, 2026

    Mylan's Sanofi Insulin Suit Mostly Survives Dismissal Bid

    A Pennsylvania federal judge Tuesday largely refused to dismiss Mylan Pharmaceuticals' antitrust lawsuit accusing Sanofi of unlawfully maintaining a monopoly in the market for injectable insulin glargine.

  • January 26, 2026

    Generics Makers Fight Cert. In Cholesterol Drug Pricing MDL

    Generic-drug makers sought to defeat a bid to certify proposed classes comprising thousands of pharmacies that indirectly purchased and resold generics at the center of sprawling price-fixing litigation, telling a Pennsylvania federal court Monday that certification would result in an "unmanageable trial."

  • January 26, 2026

    Masimo Chafes Against Apple's Bid To Duck $634M IP Verdict

    Masimo has urged a California federal court to turn down Apple's request for relief from its $634 million trial loss in the companies' patent infringement fight over the Apple Watch, arguing that the company has made "extraordinarily untimely" attempts to change the meaning of "patient monitor."

  • January 26, 2026

    Ill. Judge Trims False Ad Suit Over Abbott Formula

    An Illinois federal judge Friday dismissed several claims in a putative class action alleging Abbott Laboratories falsely advertised its toddler drinks sold under the Similac brand as nutritionally proper for children ages 12 months to 36 months, but largely allowed the parents' complaint to move forward.

  • January 26, 2026

    Novo Nordisk Faces Class Claims Over GLP-1 Patent Tactics

    A South Carolina drug company has launched a proposed class action against major pharmaceutical company Novo Nordisk, alleging it engaged in anticompetitive behavior to prolong its monopoly against generic competition for the GLP-1 drug Victoza.

  • January 26, 2026

    O'Melveny Brings On Proskauer M&A Pro In California

    O'Melveny & Myers LLP announced Monday that it added a corporate dealmaker to its Newport Beach, California, office from the Los Angeles office of Proskauer Rose LLP.

Expert Analysis

  • Series

    Law School's Missed Lessons: Mastering Time Management

    Author Photo

    Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.

  • Rare Del. Oversight Ruling Sends Governance Wake-Up Call

    Author Photo

    An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.

  • How Hyperlinks Are Changing E-Discovery Responsibilities

    Author Photo

    A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.

  • Pharma Copay Programs Raise Complex Economic Questions

    Author Photo

    The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.

  • State False Claims Acts Can Help Curb Opioid Fund Fraud

    Author Photo

    State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini.

  • Beaming Up Lessons From William Shatner's Failed Patent Bid

    Author Photo

    In a tale that boldly goes where few celebrity inventors have gone before, William Shatner's unsuccessful attempt to patent a smartphone file organization system offers insights about potential pitfalls to avoid in patent applications, say attorneys at King & Spalding.

  • The Pros And Cons Of Levying Value-Based Fees On Patents

    Author Photo

    The potential for a recurring, value-based maintenance fee on patents, while offering some benefits, raises several complications, including that it would likely exceed the U.S. Patent and Trademark Office's statutory authority and reduce research and development activities in the U.S., says Sandip Patel at Marshall Gerstein.

  • Series

    Writing Musicals Makes Me A Better Lawyer

    Author Photo

    My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.

  • Between The Lines Of EPO's Adoption Of Color Drawings

    Author Photo

    The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.

  • What Prop 65 Ruling Means For Cosmetics, Personal Care Biz

    Author Photo

    A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis.

  • Series

    Adapting To Private Practice: From Va. AUSA To Mid-Law

    Author Photo

    Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.

  • 2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls

    Author Photo

    Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.

  • Rebutting Price Impact In Securities Class Actions

    Author Photo

    Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.

  • 7 Document Review Concepts New Attorneys Need To Know

    Author Photo

    For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.

  • Ruling On Labor Peace Law Marks Shift For Cannabis Cos.

    Author Photo

    Currently on appeal to the Ninth Circuit, an Oregon federal court’s novel decision in Casala v. Kotek, invalidating a state law that requires labor peace agreements as a condition of cannabis business licensure, marks the potential for compliance uncertainty for all cannabis employers in states with labor peace mandates, say attorneys at Sheppard Mullin.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.